Image For Activity Cover
ORN Webinar Fall 2021 #3 - COVID 19 Changes to Methadone Treatment at One Clinic in Central Pennsylvania
Description

(Part 1) ORN Webinar Series: A two-part, one hour each, webinar being used to look at one clinic's approach to methadone dosing during the COVID 19 pandemic. The first hour will examine regulations in the state of Pennsylvania prior to COVID-19, the changes allowed during the pandemic, one clinic's protocol to address these changes, and outcomes for patients during this time period. The second hour will be devoted to Q&A.

If you have not registered for one of our webinars in the past, please subscribe to AOAAM (https://aoaam.org/subscribe), then login and register for the webinars.

Learning Objectives

Goals & Objectives: 

  1. To examine the heterogeneity of state guidelines for take home medication in methadone treatment
  2. To contrast PA's existing guidelines with the changes made by SAMHSA in response to COVID 19
  3. To review policies put in place by a single OTP in central PA to operationalize these changes
  4. To investigate a few basic outcomes of patient stability in recovery during this time period.
Needs Assessment

COVID 19 created a crisis in crowding at OTPs; SAMHSA's guidelines helped reduce dosing traffic and protect staff. Whether patient care/treatment continued with good outcomes or created problems relating to diversion, relapse and overdose is still under investigation nationally. I will be presenting on the procedures we followed at one OTP in central PA, and the outcomes we have seen to start the discussion on whether we need to be relaxing our rules in PA permanently.

This webinar series has been approved for a maximum 6, AOA Category 1-A CME credits, and AOA designates this for a maximum of 6, AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians 

Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Credit Statements
This webinar has been approved for a maximum 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.
Speakers
Sarah Kawasaki, MD

Dr. Kawasaki is the Director of Addictions Services at Pennsylvania Psychiatric Institute (PPI), and Assistant Professor of Psychiatry and Internal Medicine at Penn State Hershey. She designed and directs Advancement in Recovery, an opioid treatment program at the Pennsylvania Psychiatric Institute in Harrisburg, PA. She is board-certified in Internal Medicine and Addiction Medicine and has extensive clinical experience in both primary care and addiction medicine and a career interest in research to improve the delivery of evidence-based treatments to patients with substance use disorders in community-based treatment settings. PPI is the Hub of several Hub and Spoke programs in the state of Pennsylvania set up through Pennsylvania Coordinated Medication Assisted Treatment. (PACMAT) She serves as Principal Investigator of the Penn State PACMAT site, and oversees the hub and spokes in her health system. She is also leading a Project ECHO teaching initiative for the treatment of Opioid Use Disorder, where physicians and advance practitioners learn how to provide competent care confidently for patients with opioid use disorder. She either leads or is co-investigator on several studies funded by NIH, SAMHSA and NIDA, and is part of the Clinical Trials Network Appalachian Node with West Virginia University and the University of Pittsburgh.